RUTHERFORD, N.J., June 3, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) a DNA-based diagnostics company focused on developing genomic-based oncology tests and services, announced today that it has entered into a multi-year agreement to collaborate and provide PathAdvantage Associated with Cancer Genetics’ proprietary FHACT®, a FISH-based genomic test for the detection and management of cervical cancer.
Help employers find you! Check out all the jobs and post your resume.
